Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0011832936
Thu, 16.03.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Annual Results
Invitation to Cosmo’s full-year 2022 financial results and 2023 outlook webcast presentation on 23 March 2023
16.03.2023 / 06:00 GMT/BST
Dublin, Ireland – 16 March 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its [ … ]
Wed, 14.12.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Study results
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
14.12.2022 / 06:00 GMT/BST
Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in C [ … ]
Wed, 14.12.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Study results
Cosmo announces successful Phase III clinical trial of Lumeblue™ in China
14.12.2022 / 06:00 GMT/BST
Dublin, Ireland – 14 December 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the successful phase III clinical trial of Lumeblue™ in C [ … ]
Thu, 20.10.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Regulatory Approval
Cosmo announces FDA grants orphan-drug designation of
rifamycin for treatment of pouchitis
20.10.2022 / 06:00 GMT/BST
Dublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug desi [ … ]
Thu, 20.10.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Regulatory Approval
Cosmo announces FDA grants orphan-drug designation of
rifamycin for treatment of pouchitis
20.10.2022 / 06:00 GMT/BST
Dublin, Ireland – 20 October 2022. Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that the FDA has granted the orphan-drug desi [ … ]
Wed, 12.10.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
GI Genius™ named to FORTUNE 2022 “Change the World” list
12.10.2022 / 06:00 GMT/BST
Dublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release th [ … ]
Wed, 12.10.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
GI Genius™ named to FORTUNE 2022 “Change the World” list
12.10.2022 / 06:00 GMT/BST
Dublin, Ireland – 12 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that Medtronic, its global partner for GI Genius™, published a media release th [ … ]
Thu, 06.10.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
06.10.2022 / 06:15 GMT/BST
Dublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN [ … ]
Thu, 06.10.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
Medtronic wins U.S. Department of Veterans Affairs contract to provide GI Genius™ intelligent endoscopy module for artificial intelligence (AI) assisted colon cancer screening
06.10.2022 / 06:15 GMT/BST
Dublin, Ireland – 06 October 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN [ … ]
Wed, 06.07.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Conference
Invitation to Cosmo’s Half-Year 2022 Results Webcast on 28 July 2022
06.07.2022 / 06:00
Dublin, Ireland – 6 July 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2022 results on Thursday, 28 July 2022 at 07:0 [ … ]